Edition:
United States

Ionis Pharmaceuticals Inc (IONS.OQ)

IONS.OQ on NASDAQ Stock Exchange Global Select Market

57.60USD
17 Jan 2019
Change (% chg)

-- (--)
Prev Close
$57.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
377,786
52-wk High
$59.79
52-wk Low
$39.08

Select another date:

Wed, Oct 10 2018

BRIEF-Ionis Pharmaceuticals Enters New Collaboration With Partner

* IONIS ENTERS NEW COLLABORATION WITH PARTNER TO DEVELOP IONIS-FB-L RX FOR COMPLEMENT-MEDIATED DISEASES

Akcea Therapeutics genetic disease treatment gets FDA approval

Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration.

Akcea Therapeutics genetic disease treatment gets FDA approval

Oct 5 Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration.

FDA declines to approve Akcea-Ionis genetic disease drug

The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease that causes fat accumulation in the blood.

UPDATE 1-FDA declines to approve Akcea/Ionis genetic disease drug

Aug 27 The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease that causes fat accumulation in the blood.

U.S. FDA declines to approve Akcea/Ionis genetic disease drug

Aug 27 The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease which causes fat accumulation in the blood.

Select another date: